Showing 917 results
-
Ad hoc release /Ad hoc announcement pursuant to Art. 53 LR Full year Net sales grew +4% (cc1, -2% USD) with core operating income growing +8% (cc, 0% USD) IM sales grew +4% (cc, -2% USD) and core operating income…
-
Ad hoc release /Ad hoc announcement pursuant to Art. 53 LR Net sales in Q2 grew +9% (cc¹, +14% USD): Pharmaceuticals BU grew +12% (cc, +18% USD) with continued strong growth from Entresto (+46% cc), Cosentyx (+21…
-
Press release /First-of-its-kind portfolio approach in healthcare industry, aiming to increase availability and affordability of 15 medicines against cardiovascular diseases, diabetes, respiratory illnesses and…
-
Ad hoc release /Full year net sales from continuing operations¹ up 3% (cc², +3% USD): Pharmaceuticals BU grew 5% (cc) driven by Entresto (+44% cc), Zolgensma (reaching USD 0.9 billion), Cosentyx (+13% cc…
-
Press release /First results from global registrational trial of CAR T therapy, CTL019, in pediatric relapsed/refractory acute lymphoblastic leukemia Sub-group analyses from pivotal MONALEESA-2 trial of…
-
Press release /Children with SMA treated presymptomatically achieved age-appropriate motor milestones including sitting, standing and walking; required no ventilatory or feeding tube support; and had no serious,…
-
Ad hoc release /Ad hoc announcement pursuant to Art. 53 LR FDA also approved complementary diagnostic imaging agent, Locametz®, after radiolabeling with gallium-68 for the identification of PSMA-positive…
-
Press release /Transaction to include pelabresib, a late-stage BET inhibitor for myelofibrosis (MF) and tulmimetostat, an early-stage investigational dual inhibitor of EZH2 and EZH1 for solid tumors or…
-
Press release /Updated analyses from the Kisqali® pivotal Phase III MONALEESA-2 trial in hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced breast cancer to be…
-
Press release /Patients on Tasigna achieved rapid and high rates of molecular response with a very low rate of progression to advanced disease ENEST1st data confirm the favorable benefit/risk profile of…